Keyphrases
Multiple Myeloma
100%
Lenalidomide
100%
Bortezomib
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
High-risk Cytogenetics
100%
Progression-free Survival
50%
Median Overall Survival
50%
Standard Risk
50%
Mayo Clinic
25%
Highly Effective
25%
Overall Survival
25%
Overall Survival Rate
25%
5-year Survival
25%
Best Response
25%
Durable Response
25%
Median Progression-free Survival
25%
Overall Response Rate
25%
Survival Median
25%
Lenalidomide Maintenance
25%
Medicine and Dentistry
Multiple Myeloma
100%
Overall Survival
100%
Stem Cell Transplant
100%
Lenalidomide
100%
Bortezomib
100%
Dexamethasone
100%
Progression Free Survival
75%
Autologous Stem Cell Transplantation
75%
Transplantation
50%
Survival Rate
25%
Immunology and Microbiology
Overall Survival
100%
Multiple Myeloma
100%
Lenalidomide
100%
Dexamethasone
100%
Stem Cell Transplant
100%
Progression Free Survival
75%
Autologous Stem Cell Transplantation
75%
Transplant Procedure
50%
Survival Rate
25%
Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
100%
Multiple Myeloma
100%
Lenalidomide
100%
Dexamethasone
100%
Bortezomib
100%
Progression Free Survival
75%
Survival Rate
25%